Combination of chemoembolization with hepatic resection and methods of local destruction in complex treatment of colorectal cancer
The aim of the study was to prove the efficacy of the treatment regimen for patients with colorectal cancer with metastatic liver involvement. The regimen included a combination of colon and liver resection, methods of local destruction and chemotherapy. There were 126 patients with colon cancer and...
Guardado en:
Autores principales: | , , , , |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
Scientific Сentre for Family Health and Human Reproduction Problems
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fa4c2541c5f6407abb8d2a82e71f61c1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Sumario: | The aim of the study was to prove the efficacy of the treatment regimen for patients with colorectal cancer with metastatic liver involvement. The regimen included a combination of colon and liver resection, methods of local destruction and chemotherapy. There were 126 patients with colon cancer and metastases in the liver involved in the study. All tumors were adenocarcinomas of the intestinal type. Metastases in the liver affected both lobes of the liver. In the main group (64 patients), resection of the large intestine and liver resection were carried out. During the operation, radiofrequency ablation of the remaining metastases and chemoembolization of the portal vein were performed. In the postoperative period, systemic chemotherapy and chemoembolization of the hepatic artery were prescribed. In the control group (62 patients), surgery was performed on the large intestine and systemic chemotherapy was performed. Complications of the operation occurred in 18 patients (28.1 %) in the main group and 10 in patients (16.1 %) in the control group (p = 0.004). Median disease-free survival in the main group was 9.01 months, in the control group - 5.01 months (p = 0.001). Median overall survival in the main group was 13.8 months, in the control group - 9.8 months (p = 0.004). One-year overall survival in the main group was 60.93 %, in the control group - 41.93 %, two-year in the main group -17.18 %, in the control group - 6.45 %. In the control group, there were no three years survivals, and in the main group, the three-year overall survival was 4.68 %. |
---|